Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30345107 | 1.00 | PYCR1 (0.47) | PYCR1IDO1TSHRMEN1KMT2A | |
| SCHEMBL5597782 | 0.85 | CSNK2A1 (0.44) | PYCR1TSHRMEN1KMT2AMAPK1 | |
| SCHEMBL6299216 | 0.81 | PYCR1 (0.47) | PYCR1IDO1TSHRMEN1KMT2A | |
| SCHEMBL844672 | 0.81 | SLC6A4 (0.39) | PYCR1TSHRMEN1KMT2AMAPK1 | |
| SCHEMBL29680819 | 0.81 | SLC6A4 (0.39) | PYCR1TSHRMEN1KMT2AMAPK1 | |
| SCHEMBL13955284 | 0.79 | PYCR1 (0.46) | PYCR1IDO1TSHRMEN1KMT2A | |
| SCHEMBL21995434 | 0.79 | PYCR1 (0.46) | PYCR1IDO1TSHRMEN1KMT2A | |
| SCHEMBL2551704 | 0.79 | PNMT (0.48) | PYCR1IDO1MAPK1HTR2ASLC6A4 | |
| SCHEMBL307760 | 0.79 | PYCR1 (0.46) | PYCR1IDO1TSHRMEN1KMT2A | |
| SCHEMBL16998685 | 0.79 | IDO1 (0.35) | PYCR1IDO1MEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 372 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108546-A1 | GIP RECEPTOR AGONIST COMPOUNDS | LILLY CO ELI (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260070914-A1 | SUBSTITUTED PYRROLO[2,1-F][1,2,4]TRIAZIN-2-AMINES AS CDK2 AND CDK4 INHIBITORS | INCYTE CORP (US) | 2026-03-12 | — | — | US | disclosed |
| WO-2025264700-A1 | GIP RECEPTOR AGONIST COMPOUNDS | ELI LILLY AND COMPANY (US) | 2025-12-26 | — | — | WO | disclosed |
| WO-2025224262-A1 | COMBINATION THERAPIES COMPRISING A CDK2 DEGRADER AND A CDK4/6 INHIBITOR | MONTE ROSA THERAPEUTICS AG (CH) | 2025-10-30 | — | — | WO | disclosed |
| EP-4638436-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-12454525-B2 | IL4I1 inhibitors and methods of use | MERCK SHARP & DOHME LLC (US) | 2025-10-28 | — | — | US | disclosed |
| EP-4608816-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | Monte Rosa Therapeutics AG (CH) | 2025-09-03 | — | — | EP | disclosed |
| US-20250263395-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2025-08-21 | — | — | US | disclosed |
| US-20250066372-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE, LTD. (KY) | 2025-02-27 | — | — | US | disclosed |
| US-20240376048-A1 | Carboxylic Acid Containing Indanyl Compounds for the Treatment of Neurodegenerative Diseases | CELGENE CORPORATION (US) | 2024-11-14 | — | — | US | disclosed |
| WO-2000068226-A1 | 1-(P-THIENYLBENZYL)-IMIDAZOLES AS ANGIOTENSIN-(1-7) RECEPTOR AGONISTS, METHOD FOR THE PRODUCTION AND THE UTILIZATION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-11-16 | — | — | WO | disclosed |
| EP-1020452-A1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-19 | — | — | EP | disclosed |
| WO-2000003996-A1 | IMIDAZOLE DERIVATIVES WITH BIPHENYLSULFONYL SUBSTITUTION, METHOD FOR PREPARING THEM AND THEIR USE AS A DRUG OR DIAGNOSTIC AGENT | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-01-27 | — | — | WO | disclosed |
| WO-1999040064-A1 | BIPHENYLSULFONYL CYANAMIDES, METHOD FOR THE PRODUCTION THEREOF AND THEIR UTILIZATION AS A MEDICAMENT | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 1999-08-12 | — | — | WO | disclosed |
| EP-0855392-A2 | Five-membered heterocycles having biphenylsulphonyl substituents, processes for the preparation thereof, their use as medicaments or diagnostic agent and medicaments containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-07-29 | — | — | EP | disclosed |
| EP-0328643-B1 | (alpha)-HYDROPEROXYISOPROPYLPHENYL COMPOUNDS AND PROCESS FOR THEIR PREPARATION | TERUMO CORP (JP) | 1994-07-06 | — | — | EP | disclosed |
| US-5043142-A | Measuring peroxide-active substances | TERUMO KABUSHIKI KAISHA (JP) | 1991-08-27 | — | — | US | disclosed |
| EP-0328643-A1 | (alpha)-HYDROPEROXYISOPROPYLPHENYL COMPOUNDS AND PROCESS FOR THEIR PREPARATION | TERUMO KABUSHIKI KAISHA (JP) | 1989-08-23 | — | — | EP | disclosed |
| US-4539329-A | 7'-Trifluoromethyl-spiro[imidazolidine-4,3'-indoline]-2,2',5-triones as aldose reductase inhibitors | IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) | 1985-09-03 | — | — | US | disclosed |
| EP-0101149-A1 | Fluoroalkyl indoline derivatives for pharmaceutical use | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070914-A1 | SUBSTITUTED PYRROLO[2,1-F][1,2,4]TRIAZIN-2-AMINES AS CDK2 AND CDK4 INHIBITORS | CCNA1, CCNO, CDK1 | PYCR1 989/4885IDO1 3947/4885TSHR 151/4885 |
| US-20240376048-A1 | Carboxylic Acid Containing Indanyl Compounds for the Treatment of Neurodegenerative Diseases | S1PR5, S1PR2, LPAR5 | PYCR1 101/4885IDO1 801/4885TSHR 3986/4885 |
| US-20250066372-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CDK1, CDK2, CDK4 | PYCR1 2773/4885IDO1 2431/4885TSHR 3838/4885 |
| US-20260108546-A1 | GIP RECEPTOR AGONIST COMPOUNDS | GIPR, GLP1R, GCGR | PYCR1 1507/4885IDO1 2592/4885TSHR 27/4885 |
| US-20250263395-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | CDK2, SKP2, CDK1 | PYCR1 2529/4885IDO1 3498/4885TSHR 3902/4885 |
| US-12454525-B2 | IL4I1 inhibitors and methods of use | IL4I1, IL4, IL2 | PYCR1 3767/4885IDO1 623/4885TSHR 3051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.